The stock of Viridian Therapeutics Inc (VRDN) has gone up by 7.89% for the week, with a -11.57% drop in the past month and a -16.01% drop in the past quarter. The volatility ratio for the week is 5.26%, and the volatility levels for the past 30 days are 5.70% for VRDN. The simple moving average for the last 20 days is 1.94% for VRDN stock, with a simple moving average of -14.26% for the last 200 days.
Is It Worth Investing in Viridian Therapeutics Inc (NASDAQ: VRDN) Right Now?
The 36-month beta value for VRDN is at 1.11. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VRDN is 56.79M, and currently, shorts hold a 17.13% of that float. The average trading volume for VRDN on May 09, 2024 was 898.03K shares.
VRDN) stock’s latest price update
The stock price of Viridian Therapeutics Inc (NASDAQ: VRDN) has plunged by -1.59 when compared to previous closing price of 15.14, but the company has seen a 7.89% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-05-08 that Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $1.61 per share a year ago.
Analysts’ Opinion of VRDN
Many brokerage firms have already submitted their reports for VRDN stocks, with Credit Suisse repeating the rating for VRDN by listing it as a “Outperform.” The predicted price for VRDN in the upcoming period, according to Credit Suisse is $51 based on the research report published on June 14, 2023 of the previous year 2023.
BTIG Research, on the other hand, stated in their research note that they expect to see VRDN reach a price target of $46. The rating they have provided for VRDN stocks is “Buy” according to the report published on June 14th, 2023.
RBC Capital Mkts gave a rating of “Outperform” to VRDN, setting the target price at $44 in the report published on May 30th of the previous year.
VRDN Trading at -10.28% from the 50-Day Moving Average
After a stumble in the market that brought VRDN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.44% of loss for the given period.
Volatility was left at 5.70%, however, over the last 30 days, the volatility rate increased by 5.26%, as shares sank -7.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.02% lower at present.
During the last 5 trading sessions, VRDN rose by +7.89%, which changed the moving average for the period of 200-days by -25.94% in comparison to the 20-day moving average, which settled at $14.56. In addition, Viridian Therapeutics Inc saw -31.59% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRDN starting from Fairmount Funds Management LLC, who purchase 476,190 shares at the price of $21.00 back on Jan 22 ’24. After this action, Fairmount Funds Management LLC now owns 1,839,954 shares of Viridian Therapeutics Inc, valued at $9,999,990 using the latest closing price.
Meisner Lara, the Chief Legal Officer of Viridian Therapeutics Inc, sale 27 shares at $28.35 during a trade that took place back on Jun 16 ’23, which means that Meisner Lara is holding 29,971 shares at $765 based on the most recent closing price.
Stock Fundamentals for VRDN
Current profitability levels for the company are sitting at:
- -825.95 for the present operating margin
- -2.88 for the gross margin
The net margin for Viridian Therapeutics Inc stands at -757.38. The total capital return value is set at -0.39. Equity return is now at value -46.75, with -42.89 for asset returns.
Based on Viridian Therapeutics Inc (VRDN), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -8.24. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 2265.47.
Currently, EBITDA for the company is -235.37 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 3054.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.26.
Conclusion
In conclusion, Viridian Therapeutics Inc (VRDN) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
